These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 19479855)

  • 1. Dramatic efficacy of infliximab in cauda equina syndrome complicating ankylosing spondylitis.
    Cornec D; Devauchelle Pensec V; Joulin SJ; Saraux A
    Arthritis Rheum; 2009 Jun; 60(6):1657-60. PubMed ID: 19479855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance imaging of cauda equina syndrome in long-standing ankylosing spondylitis.
    Arslanoglu A; Aygun N
    Australas Radiol; 2007 Aug; 51(4):375-7. PubMed ID: 17635477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab.
    Brandt J; Haibel H; Cornely D; Golder W; Gonzalez J; Reddig J; Thriene W; Sieper J; Braun J
    Arthritis Rheum; 2000 Jun; 43(6):1346-52. PubMed ID: 10857793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uncommon complication after revision hip surgery.
    Sakellariou VI; Papadopoulos EC; Babis GC
    Orthopedics; 2014 Jun; 37(6):e608-12. PubMed ID: 24972447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lumboperitoneal shunt for treatment of dural ectasia in ankylosing spondylitis.
    Dinichert A; Cornelius JF; Lot G
    J Clin Neurosci; 2008 Oct; 15(10):1179-82. PubMed ID: 18710808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
    Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J
    Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lumboperitoneal shunting of cerebrospinal fluid versus anti-tumor necrosis factor treatment of cauda equina syndrome in ankylosing spondylitis: comment on the article by Cornec et al.
    Ea HK; Lot G; Bardin T
    Arthritis Rheum; 2010 May; 62(5):1559-60; author reply 1560-1. PubMed ID: 20178129
    [No Abstract]   [Full Text] [Related]  

  • 8. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab.
    Sieper J; Baraliakos X; Listing J; Brandt J; Haibel H; Rudwaleit M; Braun J
    Rheumatology (Oxford); 2005 Dec; 44(12):1525-30. PubMed ID: 16091396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study.
    Marzo-Ortega H; McGonagle D; Jarrett S; Haugeberg G; Hensor E; O'connor P; Tan AL; Conaghan PG; Greenstein A; Emery P
    Ann Rheum Dis; 2005 Nov; 64(11):1568-75. PubMed ID: 15829577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgA nephropathy associated with ankylosing spondylitis is not controlled by infliximab therapy.
    Jacquet A; Francois H; Frangie C; Yahiaoui Y; Ferlicot S; Micelli C; Mariette X; Durrbach A
    Nephrol Dial Transplant; 2009 Nov; 24(11):3540-2. PubMed ID: 19556300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cauda equina syndrome in ankylosing spondylitis: successful treatment with lumboperitoneal shunting.
    Ea HK; Lioté F; Lot G; Bardin T
    Spine (Phila Pa 1976); 2010 Nov; 35(24):E1423-9. PubMed ID: 21030893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab.
    Schatteman L; Gyselbrecht L; De Clercq L; Mielants H
    J Rheumatol; 2006 Jan; 33(1):82-5. PubMed ID: 16292792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis.
    Braun J; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
    Ann Rheum Dis; 2005 Feb; 64(2):229-34. PubMed ID: 15388511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cauda equina syndrome in ankylosing spondylitis.
    Jordan AS; Spencer DG; Howe GB; Manolios N
    J Clin Rheumatol; 2013 Apr; 19(3):163. PubMed ID: 23519172
    [No Abstract]   [Full Text] [Related]  

  • 15. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
    Braun J; Baraliakos X; Brandt J; Listing J; Zink A; Alten R; Burmester G; Gromnica-Ihle E; Kellner H; Schneider M; Sörensen H; Zeidler H; Sieper J
    Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-body magnetic resonance imaging evaluation of widespread inflammatory lesions in a patient with ankylosing spondylitis before and after 1 year of treatment with infliximab.
    Appel H; Hermann KG; Althoff CE; Rudwaleit M; Sieper J
    J Rheumatol; 2007 Dec; 34(12):2497-8. PubMed ID: 18061968
    [No Abstract]   [Full Text] [Related]  

  • 17. Cauda equina syndrome and dural ectasia: rare manifestations in chronic ankylosing spondylitis.
    Liu CC; Lin YC; Lo CP; Chang TP
    Br J Radiol; 2011 Jun; 84(1002):e123-5. PubMed ID: 21606066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system.
    Braun J; Baraliakos X; Golder W; Brandt J; Rudwaleit M; Listing J; Bollow M; Sieper J; Van Der Heijde D
    Arthritis Rheum; 2003 Apr; 48(4):1126-36. PubMed ID: 12687557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sézary syndrome in a patient receiving infliximab for ankylosing spondylitis.
    Dauendorffer JN; Rivet J; Allard A; Bachelez H
    Br J Dermatol; 2007 Apr; 156(4):742-3. PubMed ID: 17263820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.